Revolution Medicines, Inc. Stockholders Equity

Quick Answer

Revolution Medicines, Inc. reported Stockholders Equity of $1.63 billion for fiscal year 2025.

Revolution Medicines, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $1.63B -28.0%
2024 $2.27B +24.0%
2023 $1.83B +166.5%
2022 $685.19M +13.7%
2021 $602.57M +26.9%
2020 $474.68M +411.1%
2019 -$152.57M -40.7%
2018 -$108.42M -60.1%
2017 -$67.72M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $1.60B +2.0% -14.4%
June 30, 2025 $1.87B +15.2% -10.2%
March 31, 2025 $2.08B +20.4% -8.3%
December 31, 2024 $2.27B +24.0% +44.6%
September 30, 2024 $1.57B +87.0% -3.2%
June 30, 2024 $1.62B +73.9% -6.2%
March 31, 2024 $1.73B +81.2% -5.5%
December 31, 2023 $1.83B +166.5% +118.1%
  • Revolution Medicines, Inc. showed a decrease of -28.0% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2017–2025 period, Revolution Medicines, Inc.’s stockholders equity has grown by 2509.0% (from -$67.72 million to $1.63 billion).
  • The most recent figure is from Revolution Medicines, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment